Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

NCT05589610 is registered in ClinicalTrials.gov with Equillium as lead sponsor.

NCT NCT05589610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05589610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
Lead sponsor
Equillium
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2022
Completion date
April 30, 2024
Enrollment
36 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia, alopecia areata, alopecia totalis, alopecia universalis